Related Experiment Video
Updated: Jan 13, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy
Ruofan Shi1,2, Yongle Zhan1,3, Ruochen Ma1
1Division of Urology, Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
JAMA Oncology
|January 8, 2026
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may offer antitumor benefits in prostate cancer. Their use during hormone therapy was linked to delayed androgen deprivation therapy failure, suggesting a potential oncologic advantage.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Preliminary evidence suggests sodium-glucose cotransporter 2 (SGLT2) inhibitors may possess antitumorigenic properties.
- The potential benefits of SGLT2 inhibitors in prostate cancer treatment remain largely unexplored.
- Understanding their impact on outcomes during hormone therapy is crucial for developing adjunct treatment strategies.
Purpose of the Study:
- To investigate the association between SGLT2 inhibitor use and clinical outcomes in prostate cancer patients undergoing hormone therapy.
- To evaluate the efficacy of SGLT2 inhibitors in delaying treatment failure and improving survival in this patient population.
Main Methods:
- A population-based, sequential target trial emulation using Hong Kong electronic health records (1993-2025).
- Inclusion of adult men with prostate cancer initiating androgen deprivation therapy (ADT).
- Analysis of SGLT2 inhibitor use (dapagliflozin, empagliflozin) versus non-use, assessing time to ADT failure, next-generation hormonal agent failure, disease-specific survival, and overall survival.
Main Results:
- Among 14,223 patients, SGLT2 inhibitor use was associated with a reduced risk of ADT failure (HR, 0.63) and next-generation hormonal agent failure (HR, 0.44).
- Metformin monotherapy showed no association with disease progression but improved overall survival (HR, 0.59).
- No significant differences were observed between dapagliflozin and empagliflozin.
Conclusions:
- SGLT2 inhibitor use is associated with delayed hormone therapy failure in prostate cancer patients.
- These findings suggest a potential oncologic benefit of SGLT2 inhibitors beyond their glucose-lowering effects.
- SGLT2 inhibitors show promise as a potential adjunct treatment for prostate cancer.
More Related Videos
Related Concept Videos
01:55Secondary Active Transport
136.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.8K
01:32Secondary Active Transport
9.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
01:27Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
01:06Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593